Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Metadata
Title
Effect of Ethanol on Postprandial Duodenojejunal Motility in Humans
Authors
Thomas Schmidt
Roland Eberle
Albrecht Pfeiffer
Herbert Kaess
Publication date
01-08-1997
Publisher
Kluwer Academic Publishers-Plenum Publishers
Published in
Digestive Diseases and Sciences / Issue 8/1997
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1023/A:1018892827554

Other articles of this Issue 8/1997

Digestive Diseases and Sciences 8/1997 Go to the issue

OriginalPaper

Gallstone Dissolution with Oral Bile Acid Therapy Importance of Pretreatment CT Scanning and Reasons for Nonresponse

OriginalPaper

Serum Antibodies Against Helicobacter pylori Proteins VacA and CagA Are Associated with Increased Risk for Gastric Adenocarcinoma

OriginalPaper

Effect of Enprostil on Omeprazole-Induced Hypergastrinemia and Inhibition of Gastric Acid Secretion in Peptic Ulcer Patients

OriginalPaper

Mitogenic Properties of Human Gastric Juice

OriginalPaper

Serum HCV-RNA and Liver Histologic Findings in Patients with Long-Term Normal Transaminases

OriginalPaper

Lack of Hepatocyte Growth Factor Receptor (c-met) Gene Expression in Fulminant Hepatic Failure Livers Before Transplantation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits